Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Genet. 2013 Aug;29(8):488-97. doi: 10.1016/j.tig.2013.05.005. Epub 2013 Jun 4.

Mitochondrial disorders: aetiologies, models systems, and candidate therapies.

Author information

1
Smurfit Institute of Genetics, School of Genetics & Microbiology, Trinity College Dublin, Dublin 2, Ireland. gjfarrar@tcd.ie

Abstract

It has become evident that many human disorders are characterised by mitochondrial dysfunction either at a primary level, due to mutations in genes whose encoded products are involved in oxidative phosphorylation, or at a secondary level, due to the accumulation of mitochondrial DNA (mtDNA) mutations. This has prompted keen interest in the development of cell and animal models and in exploring innovative therapeutic strategies to modulate the mitochondrial deficiencies observed in these diseases. Key advances in these areas are outlined in this review, with a focus on Leber hereditary optic neuropathy (LHON). This exciting field is set to grow exponentially and yield many candidate therapies to treat this class of disease.

KEYWORDS:

Leber hereditary optic neuropathy; gene therapy; mitochondrial disease

PMID:
23756086
DOI:
10.1016/j.tig.2013.05.005
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center